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KEY MESSAGE
In this study, the use of sympathomimetics was positively associated with sperm motility in men of subfertile 
couples. Further investigation is necessary to test whether men of subfertile couples could benefit from this 
potential second use of sympathomimetics.
ABSTRACT
Research question: Is there an association between the use of sympathomimetics for asthmatic disease and semen 
quality in humans?
Design: Between 2007 and 2012 a prospective cohort study was conducted among couples visiting the preconception 
counselling clinic at a tertiary hospital in the Netherlands. The study included 882 men of subfertile couples and 
information on medication use was obtained from self-administered questionnaires. Moreover, data on semen 
parameters were retrieved from medical records.
Results: The study population of men revealed a mean (± SD) age of 34 ± 4 years with a mean body mass index (BMI) 
of 26.1 ± 2.3 kg/m2, and sympathomimetic use was reported by 3.6%. The use of sympathomimetics was positively 
associated with a 10% higher sperm motility (beta 10.265; 95% confidence interval [CI] 3.258–17.272) after adjustment 
for smoking, alcohol use, age, geographic background, BMI, folic acid supplement use, the four astronomical seasons 
and asthma/bronchitis. Subgroup analysis between men with total motile sperm count (TMSC) < or ≥10 million 
showed that this association remained (P ≤ 0.001) after adjustment for these confounders. After adjustment for 
confounders the sperm concentration was also positively associated with the use of sympathomimetics, but only in 
men with TMSC ≥10 million (beta 0.300; 95% CI 0.032–0.568).
Conclusions: These preliminary data show the potential benefits of the use of sympathomimetics to improve sperm 
motility in men of subfertile couples, which needs further investigation.
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INTRODUCTION
Worldwide one out of six couples experiences subfertility, which is defined as the failure 
to conceive after 1 year of regular 
unprotected intercourse with the same 
partner (European Society of Human 
Reproduction and Embryology, 2016; 
World Health Organization, 2010). Of all 
subfertile couples, 20–30% is explained 
by male subfertility only and in 25–40% 
both male and female subfertility are 
found (European Society of Human 
Reproduction and Embryology, 2016). 
Unfortunately, only a few medical 
treatments are available for male 
subfertility.
Research from the past two decades has 
shown that semen quality is influenced by 
several conditions and modifiable factors, 
such as obesity, nutrition, smoking 
and medication use (CBS StatLine 
Netherlands, 2015;Hayashi et al., 2008; 
Huijgen et al., 2016, 2017; Samplaski 
and Nangia, 2015). In the Netherlands, 
the overall use of medication of the 
male population of reproductive age 
(20–60 years) is approaching 55% 
(CBS StatLine Netherlands, 2015). 
Subfertility resulting from medication-
induced endocrine malfunction or 
injury to germ cells is a largely neglected 
clinical problem (Hayashi et al., 2008; 
Huijgen et al., 2016, 2017; Samplaski 
and Nangia, 2015). The exact potentially 
toxic effect on the gonads of many 
commonly used medicines is, however, 
still largely unknown (Fody and Walker, 
1985; Hayashi et al., 2005; Schlegel 
et al., 1991; Semet et al., 2017; Sjoblom 
et al., 1998), as is the impact of chronic 
diseases on male fertility (Eisenberg 
et al., 2015; Global Initiative for Asthma, 
2017; Hayashi et al., 2008).
An example of a very common chronic 
disease with an overall prevalence in the 
Netherlands of 6% is asthma/bronchitis 
(Boerdam and Knoops, 2016). According 
to the guidelines of the Dutch College 
of General Practitioners, these chronic 
diseases are treated with short-acting 
inhaled sympathomimetics, a low/
high dose inhaled glucocorticoid or 
combination of these medicines (The 
Dutch College of General Practitioners, 
2007). In the Netherlands, around 
5.6% of males of reproductive age uses 
medication for asthma/bronchitis (CBS 
StatLine Netherlands, 2015). As the 
adrenergic receptors on which these 
medications act are also present in the 
reproductive system, it is postulated 
that sympathomimetics can also affect 
spermatogenesis. Therefore, this study 
aimed to assess associations between 
the use of sympathomimetics and sperm 
quality in men of subfertile couples.
MATERIALS AND METHODS
Study population
Between 2007 and 2012, couples 
contemplating pregnancy and visiting 
the outpatient clinic of the Department 
of Obstetrics and Gynecology at the 
Erasmus University Medical Center 
(Erasmus MC), Rotterdam, the 
Netherlands, were offered preconception 
counselling. This special outpatient 
clinic, ‘Achieving a Healthy Pregnancy’ 
(Hammiche et al., 2011), was visited 
by 2365 men, of whom 2166 provided 
written informed consent (METC 
Erasmus MC 04202-77). Men for whom a 
semen analysis was not performed within 
0–70 days prior to the visit or 21 days 
after the visit were excluded. This window 
covers the 10 weeks of spermatogenesis 
during which medication use was 
assessed and reduces confounding 
by counselling as this window was 
independent of exposures and bias due 
to the exclusion of conditions affecting 
semen parameters. Men with semen 
samples provided by microsurgical 
epididymal sperm aspiration (MESA), 
percutaneous epididymal sperm 
aspiration (PESA) or retrograde 
ejaculation, or with incomplete data or 
no data on medication use, were also 
excluded. This resulted in 882 men for 
further evaluation (FIGURE 1). The study 
protocol was approved by the Medical 
Ethical and Institutional Review Board of 
the Erasmus MC on 25 June 2013.
Data collection
At study entry, all participants completed 
a self-administered questionnaire 
covering (non)-medical conditions at 
enrolment, which were thoroughly 
checked by the researcher during 
the preconception visit, during which 
anthropometric measurements (height, 
weight, BMI, waist–hip ratio and blood 
pressure) were also obtained (Hammiche 
et al., 2011).
Medication use
Information on medication use was 
obtained from self-administered 
questionnaires and was divided 
according to the Anatomical Therapeutic 
Chemical (ATC) classification system 
(WHO Collaborating Centre for 
Drug Statistics Methodology, WHO 
Collaborating Centre for Drug Statistics 
Methodology, 2017). In this study 
population short-acting and long-acting 
beta-2 adrenergic receptor agonists were 
used for asthma/bronchitis, as well as 
inhaled corticosteroids (either alone or 
combined). Information on dosage and 
duration was not available.
Semen analysis
Semen samples were collected via 
masturbation after a required abstinence 
period of 3–5 days. Within 1 h, 
samples were liquefied and the semen 
parameters ejaculate volume, sperm 
concentration, percentage progressive 
(type A+B) and immotile spermatozoa 
(type C+D) were assessed according to 
World Health Organization guidelines 
(World Health Organization, 2010). 
Total sperm count was calculated as the 
product of ejaculate volume and sperm 
concentration. Total motile sperm count 
(TMSC) was calculated as the product of 
ejaculate volume, sperm concentration 
and percentage progressive motile 
spermatozoa (type A+B). Normospermia 
was defined as TMSC ≥10 million. All 
semen analyses were performed by 
expert laboratory staff at the Erasmus 
MC. Semen samples were not routinely 
collected as part of the study, but only 
on the clinical indication of subfertility. 
Semen parameters were therefore 
retrieved from medical records to obtain 
all the data required for this study.
Statistical analyses
Primary analyses included descriptive 
statistics providing characteristics of the 
study sample, expressed as medians with 
interquartile ranges or absolute numbers 
with percentages and were compared 
using either Mann–Whitney U-tests or 
chi-squared tests. A normal distribution 
of the semen parameters was achieved 
with root transformation of ejaculate 
volume and sperm count, and fourth root 
transformation of sperm concentration 
and TMSC. Univariable and multivariable 
linear regression models were applied 
to study associations between the 
use of sympathomimetics and semen 
parameters.
After the crude analysis, an adjusted 
model was constructed including the 
potential confounders body mass 
index (BMI), alcohol use, smoking, 
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geographic background, age and folic 
acid supplement use, based on their 
associations with semen parameters. 
An adjustment was also made for 
the four astronomical seasons. As a 
final step, confounding by indication 
was addressed because this is a bias 
frequently encountered in observational 
epidemiologic studies of medication 
effects. To do this, an additional 
adjustment was made for the presence 
or absence of asthmatic disease. Finally, 
a similar multivariable linear regression 
analysis was performed, stratified for men 
with a TMSC < or ≥10 million. Estimates 
are expressed by regression coefficients 
(beta) with confidence intervals (95% CI). 
All analyses were performed using SPSS 
FIGURE 1 Flow diagram of included and excluded men (MESA = microsurgical epididymal sperm aspiration; PESA = percutaneous epididymal 
sperm aspiration).
4 RBMO  VOLUME 00  ISSUE 0  2020
Statistics for Windows, Version 21.0 (IBM 
Corp., Armonk, NY, USA). P-values <0.05 
were considered statistically significant.
RESULTS
General characteristics of the study 
population (n = 882) and excluded 
population (n = 1483) are presented in 
Supplementary Table 1. Included men 
were slightly younger (34 versus 35 
years; P < 0.001) and more often used 
alcohol (71.5 versus 66.9%; P < 0.05). 
Overall, the study population were aged 
34 ± 4 years (mean ± SD), with a BMI of 
26.1 ± 2.3 kg/m2, and sympathomimetic 
use was reported by 3.6%. TABLE 1 shows 
the general characteristics of the study 
population divided into men using 
sympathomimetics (n = 32) and those 
not using any medication (n = 850). 
Sympathomimetic users showed a higher 
percentage of folic acid supplement use 
(24.1% versus 6.0%; P < 0.001) and a 
higher percentage of progressive motile 
spermatozoa (48% versus 38%; P < 0.05) 
than non-medication users (TABLE 1).
After adjustment for potential 
confounders, i.e. smoking, alcohol 
use, age, geographic background, BMI, 
folic acid supplement use and the four 
astronomical seasons, multivariable linear 
regression analyses revealed that the use 
of sympathomimetics compared with 
no medication use remained positively 
associated with a 10% higher percentage 
of progressive motile spermatozoa 
(model 1; beta = 10.859; 95% CI 
3.977–17.742). By additionally adjusting 
for asthmatic disease, the significantly 
positive association between the use 
of sympathomimetics and percentage 
progressive motile spermatozoa 
remained (model 2; beta = 10.265; 95% 
CI 3.258–17.272) (TABLE 2).
In a subgroup analysis of men with 
TMSC < or ≥10 million, these 
positive associations remained, but 
only in men with TMSC <10 million 
(Supplementary Table 2). Moreover, 
after adjustment for potential 
confounders, sperm concentration 
was also positively associated with the 
use of sympathomimetics, but was 
only statistically significant in men with 
TMSC ≥10 million (Supplementary 
Table 2). Stratifying the study population 
in men with TMSC < or ≥3 million 
and in men with TMSC < or ≥1 
million did not significantly change 
the associations, although the use of 
TABLE 1 GENERAL CHARACTERISTICS OF THE STUDY POPULATION OF MEN OF SUBFERTILE COUPLES VISITING THE 
PRECONCEPTION OUTPATIENT CLINIC ‘ACHIEVING A HEALTHY PREGNANCY’ (N = 882)
Users of sympathomimetics (n = 32) Non-medication users (n = 850)
Age (years) 35 (32–39) 34 (30–39)a
BMI (kg/m2) 27.4 (24.4–30.7)b 26.1 (23.9–28.5)c
Geographic background (Dutch) 21 (65.6) 538 (63.6)d
Smoking (Yes) 7 (21.9) 281 (33.1)e
Alcohol (Yes) 27 (84.4) 602 (71.0)f
Recreational drugs (Yes) 1 (3.1) 65 (7.6)
Folic acid supplement use (Yes) 7 (24.1)g** 45 (6.0)h
Semen parameters: Lower reference limit 
(WHO, 2010)
 Ejaculate volume (ml) 2.75 (1.45–3.60) 2.80 (1.80–3.90) 1.5
 Sperm concentration (106/ml) 33 (11–81) 26 (9–59) 15
 Total sperm count (106/ejaculate) 60.8 (17.5–182) 64.8 (19.7–146) 39
 Total motile sperm count (106/ejaculate) 30.8 (7.5–89.4) 24.5 (4.1–68.4) 10
 Progressive motile spermatozoa (A+B) (%) 48 (39–53)* 38 (23–49) 32
Duration of sexual abstinence (days) 4 (3–5)i 4 (3–7)j
Values are expressed as median (IQR) or number (%); chi-squared and Mann–Whitney tests were performed: * P < 0.05; ** P < 0.001.
Missing items: twoa for age, oneb and 36c for BMI, fourd for geographic background, onee for smoking, twof for alcohol, and threeg and 45h for folic acid supplement use, 22i 
and 340j for duration of sexual abstinence.
BMI = body mass index.
TABLE 2 UNI- AND MULTIVARIABLE LINEAR REGRESSION MODELS OF MEN OF SUBFERTILE COUPLES (N = 882)
Sympathomimetics Ejaculate volume 
√(ml) beta (95% CI)
Sperm concentration 
4√(106/ml) beta (95% 
CI)
Sperm count √(106/





(A+B%) beta (95% 
CI)
Unadjusted (n = 882) –0.103 (–0.268, 0.063) 0.166 (–0.149, 0.481) 0.465 (–1.732, 2.662) 0.161 (–0.212, 0.534) 8.224 (1.798, 14.651)*
Model 1 (n = 795) –0.119 (–0.298, 0.060) 0.287 (–0.049, 0.623) 1.123 (–1.210, 3.456) 0.301 (–0.097, 0.699) 10.859 (3.977, 17.742)*
Model 2 (n = 795) –0.111 (–0.293, 0.072) 0.279 (–0.062, 0.621) 1.093 (–1.284, 3.470) 0.285 (–0.121, 0.690) 10.265 (3.258, 17.272)*
Note: data depicted as beta and confidence interval (95% CI).
* P < 0.05. The regression coefficient (beta) indicates the increase or decrease (–) change per unit of the sperm parameter. Model 1: adjusted for smoking, alcohol use, age, 
geographic background, BMI, folic acid supplement use and the four astronomical seasons. Model 2: model 1 with additional adjustment for asthma/bronchitis.BMI = body 
mass index; CI = confidence interval.
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sympathomimetics was only significantly 
associated with sperm motility in men 
with TMSC ≥1 and ≥3 million (model 
2; beta = 6.890; 95% CI 1.409–12.371 
and model 2; beta = 8.205; 95% CI 
2.290–14.120 for TMSC ≥3 million and 
≥1 million, respectively) (Supplementary 
Table 3). Moreover, in men with TMSC 
≥3 million, use of sympathomimetics was 
significantly associated with less ejaculate 
volume after adjustment for potential 
confounders (model 2; beta = –0.196; 
95% CI –0.379–0.012) (Supplementary 
Table 3).
As corticosteroids were also used by 
some men in the study population, 
associations between corticosteroid use 
and semen quality were also studied, but 
showed no significant associations (data 
not shown).
DISCUSSION
This study demonstrates that the use 
of sympathomimetics is associated 
with a significantly higher percentage 
progressive motile spermatozoa (type 
A+B) independent of corticosteroid 
use. Moreover, in men with TMSC 
≥10 million, sperm concentration 
was also positively associated with 
the use of sympathomimetics. These 
positive associations remained after 
adjustment for potential confounders and 
confounding by indication.
Sympathomimetics are agonists for 
beta-adrenergic receptors, a class of G 
protein-coupled receptors, resulting in 
stimulation of the sympathetic nervous 
system. This activation of beta-adrenergic 
receptors is followed by activation of 
the enzyme adenylate cyclase, which 
in turn leads to activation of the 
secondary messenger cyclic adenosine 
monophosphate (cAMP), which activates 
protein kinase A (PKA) (Rang and Dale, 
2012). Testicular spermatozoa develop 
the capacity for motility during transit 
through the epididymis (Dacheux and 
Dacheux, 2014). Therefore, a possible 
explanation for the positive association 
between the use of sympathomimetics 
and percentage progressive motile 
spermatozoa may be related to the 
increase in cAMP and PKA, because 
these signalling pathways, together with 
the calcium pathway, are known to be the 
most central to the regulation of sperm 
motility (Turner, 2006). This hypothesis 
is substantiated by Esposito et al. (2004), 
showing a time-dependent recovery of 
sperm motility in mice with impaired 
motility, after loading with cAMP.
Several studies have indicated that normal 
function of the alpha-adrenergic receptor 
is necessary for normal contraction of 
the vas deferens and seminal vesicles and 
consequent sperm ejaculation (Sanbe 
et al., 2007; van Dijk et al., 2006). By 
stimulation of the beta-receptors, the 
vasoconstrictive effect of the alpha-
receptors decreases. This may explain the 
negative trend this study found between 
the use of sympathomimetics and 
ejaculate volume. The significantly positive 
association with sperm concentration 
found in the subgroup of men with TMSC 
≥10 million is suggested to be a direct 
consequence of the decrease in ejaculate 
volume, as sperm concentration is the 
product of sperm count multiplied by 
ejaculate volume.
The FDA states that sympathomimetics 
are safe to use on a daily basis for the 
indication of asthmatic disease, but 
surprisingly, data on the effects on 
semen parameters are missing (US Food 
and Drug Administration). In future, 
the use of sympathomimetics could be 
considered to enhance sperm motility 
in subfertile men, especially because 
of the relatively mild adverse effects 
and acceptable route of administration. 
This is of interest because of the few 
therapeutic alternatives to enhance male 
fertility with selective oestrogen receptor 
modulators, such as clomiphene citrate 
and tamoxifen, with more frequent 
adverse effects than sympathomimetics, 
such as nausea, headache, alteration 
in libido, visual field changes and 
gynecomastia (Ramasamy et al., 2014; 
Siddiq and Sigman, 2002; Wiehle et al., 
2014).
This study is limited by the fact that 
only one semen analysis was taken 
into account, which does not account 
for intra-individual variation in semen 
parameters. Because the study only 
included men as cases when they used 
the specific medication at the time of the 
actual study visit, the number of cases 
is relatively small. Some heterogeneity 
caused by an unknown combination 
of diseases and the fact that not every 
disease is always treated could have 
negatively affected the estimates. 
Moreover, dose–response effects could 
not be studied to further estimate 
causality of the observed associations. 
Lastly, this study was performed in men 
of subfertile couples and therefore the 
external validity is limited. However, the 
majority of men had normospermia 
with most parameters above the lower 
reference limit, which in contrast, does 
makes the results generalizable to all men.
Major strengths of this study are the 
standardized data collection by a trained 
researcher of a large group of men of 
subfertile couples visiting one tertiary 
hospital and the fact that semen analyses 
were performed at one laboratory. 
Moreover, the time period between 
measurement of sperm parameters 
and study entry visit was strictly set, 
so it reflects the sensitive exposure 
window of male spermatogenesis of 
approximately 70 days. Besides, several 
confounders, including the use of other 
medicines, were included in the analyses, 
confounding by indication was excluded 
and stratified analyses were performed 
in order to contribute to personalized 
medicine in the future.
The current study demonstrates that the 
use of sympathomimetics is positively 
associated with sperm motility in men 
of subfertile couples. Moreover, in 
men with TMSC ≥10 million, use of 
sympathomimetics was also positively 
associated with sperm concentration. 
This explorative data suggests that male 
subfertility could be a new indication for 
a secondary use of sympathomimetics, a 
novel finding that needs to be interpreted 
with caution and emphasizes the need 
for further research on causality.
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